Bavarian Nordic achieved positive data from its Phase II study investigating the safety and immune effects of its universal RSV vaccine, MVA-BN RSV in an older adult population.  In a planned follow-up analysis, there was an approximately 1.5-fold increase in IgA antibodies over baseline levels, with peak increases seen in the weeks immediately following vaccination. The boosting effect was more pronounced in individuals with a lower baseline mucosal IgA at the time of vaccination. This obser...